Whether this is achieved via specifically targeting IL-1 signaling via anti-IL-1 antibodies or antagonists, such as Anakinra, or targeted deletion of IL1R1+ subtypes of fibroblasts in the TME (for example via linked markers such as PDPN) requires further research, but the potential for more efficient therapies is evident, especially for patients with hard-to-treat, highly stromal subtypes of colorectal cancer. Here, IL1A is linked to colorectal cancer.